HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:8/27/2014)... Angeles, CA (PRWEB) August 27, 2014 Jaha ... To do this, Jaha invested in creating the industry’s most ... by adding functions that no other apps possess. ... a tracker that differentiates in three simple steps: locate, challenge ... launch on Tuesday, Aug 26, 2014 to garner support and ...
(Date:8/27/2014)... Nava Beauty Store and Spa aims to ... from those seeking luxury care products to the everyday person ... end luxurious brands like Valmont and Elemis to cater to ... like Dermalogica and Bliss to provide easy to use and ... offer purely organic skin care products such as Jurlique, Rahua ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Many patients ... reality is that depression has a mortality rate of ... bi-polar disorder is slightly less, though it's offset by ... 7%. In order to properly treat and manage ... bi-polar, medication must be taken as directed. Missed ...
(Date:8/27/2014)... Australia (PRWEB) August 27, 2014 ... erratic climatic conditions and fluctuations in global supply and ... the past five years. The industry derives a large ... are subject to global market dynamics, with supply and ... Brazil and India. A strong Australian dollar for the ...
(Date:8/27/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND REGENERATIVE PRODUCTS , the global market for advanced ... by 2014-end to $42.2 billion by 2019, with a ... to 2019. New technologies and an increasingly older population ... market. , While there are many conventional and generally ...
Breaking Medicine News(10 mins):Health News:Jaha, Inc. The Most Affordable Fitness Band in the Market Released on Kickstarter 2Health News:Nava Beauty Store Announce Grand Opening in Great Neck, New York 2Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 3
(Date:8/27/2014)... , Aug. 27, 2014  After the February 2014 ... Injury billing solution for medical practices and management ... toward the new software. "The feedback has ... Thompson . "The sheer number of demos and new ... need was for these types of software features." ...
(Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
(Date:8/26/2014)... -- Intelomed is pleased to announce that Mary ... the Vice President of Clinical Affairs. With over 30 ... industry, Kay,s experience in taking medical technology and associated ... global expansion, is a valuable addition to the Intelomed ... our team, and I am confident her focused and ...
Breaking Medicine Technology:Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2
Cached News: